Share on LinkedInShare on LinkedIn

ARTICLE · 13 APRIL 2011

Working Example No Longer Required to Patent Monoclonal Antibodies

On June 4, 2010, the Patent Appeal Board ("Board") determined that claims to a monoclonalantibody are enabled where the antigen is a novel polypeptide which has been fully characterized (for example by complete amino acid sequence).

CanadaIntellectual Property

Confidential Reasons released June 4, 2010

Case:

Immunex Corporation Patent Application No. 583,988 (Re) (Patent Appeal Board)

Nature of Case:

Appeal of Final Rejection - section 30(6) Patent Rules

Successful Party:

Immunex Corporation

Summary:

On June 4, 2010, the Patent Appeal Board ("Board") determined that claims to a monoclonalantibody are enabled where the antigen is a novel polypeptide which has been fully characterized (for example by complete amino acid sequence). An Applicant can now claim a monoclonal antibody that is immunoreactive to the fully characterized novel polypeptide without having made or deposited a specific embodiment. The Board permitted the Applicant to make certain amendments which would overcome other objections the Commissioner had and thus enable the patent application to be allowed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from